Heat shock proteins as novel therapeutic targets in cancer

In Vivo

Volumn 22, Issue 3, 2008, Pages 311-316

  Soo, Eliza T L ^a   Yip, George W C ^a   Lwin, Zin Mar ^a   Kumar, Srinivasan D ^a   Bay, Boon Huat ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

17 allyl 17 dimethoxygeldanamycin; Anticancer agents; Geldamycin; Heat shock protein (HSPs); HSP 91; HSP inhibitions; Molecular Chaperones; Review

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELDANAMYCIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90; TANESPIMYCIN;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER INVASION; CELL PROTECTION; CLINICAL TRIAL; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; METASTASIS POTENTIAL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TUMOR VASCULARIZATION;

EID: 46049094024     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Ritossa F: A new puffing pattern induced by temperature shock and DNP in Drosophila. Cell Mol Life Sci 18: 571-573, 1962.
2. Tissieres A, Mitchell HK and Tracy UM: Protein synthesis in salivary glands of Drosophila melanogaster: relation to chromosome puffs. J Mol Biol 84: 389-398, 1974.
3. Young JC, Agashe VR, Siegers K and Hard FU: Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev Mol Cell Biol 5: 781-791, 2004.
4. Gao H, Wang Y, Liu X, Yan T, Wu L, Alm E, Arkin A, Thompson D and Zhou J: Global transcriptome analysis of the heat shock response of Shewanella oneidensis. J Bacteriol 186: 7796-7803, 2004.
5. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E and Kroemer G: Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 5: 2592-2601, 2006.
6. Pockley AG: Heat shock proteins as regulators of the immune response. Lancet 362: 469-476, 2003.
7. Voellmy R: Feedback regulation of the heat shock response. Handb Exp Pharmacol 172: 43-68, 2006.
8. Hartl FU: Molecular chaperones in cellular protein folding. Nature 381: 571-579, 1996.
9. Csermely P: Proteins, RNAs and chaperones in enzyme evolution: a folding perspective. Trends Biochem Sci 22: 147-149, 1997.
10. Soti C and Csermely P: Chaperones and aging: role in neurodegeneration and in other civilizational diseases. Neurochem Int 41: 383-389, 2002.
11. Powers MV and Workman P: Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett 581: 3758-3769, 2007.
12. Soti C and Csermely P: Aging and molecular chaperones. Exp Gerontol 38: 1037-1040, 2003.
13. Bukau B and Horwich AL: The Hsp70 and Hsp60 chaperone machines. Cell 92: 351-366, 1998.
14. Whitesell L and Lindquist SL: HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-772, 2005.
15. Takayama S, Reed JC and Homma S: Heat-shock proteins as regulators of apoptosis. Oncogene 22: 9041-9047, 2003.
16. Neckers L: Heat shock protein 90: the cancer chaperone. J Biosci 32: 517-530, 2007.
17. Kimura E, Enns RE, Alcaraz JE, Arboleda J, Slamon DJ and Howell SB: Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. J Clin Oncol 11: 891-898, 1993.
18. Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ and McGuire WL: Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Nad Cancer Inst 85: 570-574, 1993.
19. Ralhan R and Kaur J: Differential expression of Mr 70,000 heat shock protein in normal, premalignant, and malignant human uterine cervix. Clin Cancer Res 1: 1217-1222, 1995.
20. Chant ID, Rose PE and Morris AG: Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry. Br J Haematol 90: 163-168, 1995.
21. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
22. Neckers L and Ivy SP: Heat shock protein 90. Curr Opin Oncol 15: 419-424, 2003.
23. Calderwood SK, Khaleque MA, Sawyer DB and Ciocca DR: Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31: 164-172, 2006.
24. Rahmani M, Reese E, Dai Y, Bauer C, Kramer LB, Huang M, Jove R, Dent P and Grant S: Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ cells sensitive and resistant to STI571 (imatinib mesylate) in association with downregulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol Pharmacol 67: 1166-1176, 2005.
25. Lane DP, Midgley C and Hupp T: Tumour suppressor genes and molecular chaperones. Philos Trans R Soc Lond B Biol Sci 339: 369-372, 1993.
26. Pinhasi-Kimhi O, Michalovitz D, Ben-Zeev A and Oren M: Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature 320: 182-184, 1986.
27. Hollstein M, Sidransky D. Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
28. Sreedhar AS and Csermely P: Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy: a comprehensive review. Pharmacol Ther 101: 227-257, 2004.
29. Beere HM: Stressed to death: regulation of apoptotic signaling pathways by the heat shock proteins. Sci STKE 9: RE1, 2001.
30. Workman P: Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 10: 47-51, 2004.
31. Wadhwa R, Taira K and Kaul SC: An Hsp70 family chaperone, mortalin/ mthsp70/PBP74/Grp75: what, when, and where? Cell Stress Chaperones 7: 309-316, 2002.
32. Zhou J, Schmid T, Frank R and Brune B: PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. J Biol Chem 279: 13506-13513, 2004.
33. Sun J and Liao JK: Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol 24: 2238-2244, 2004.
34. Ciocca DR and Calderwood SK: Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10: 86-103, 2005.
35. Eustace BK and Jay DG: Extracellular roles for the molecular chaperone, hsp9O. Cell Cycle 3: 1098-1100, 2004.
36. Thomas X, Campos L, Le QH and Guyotat D: Heat shock proteins and acute leukemias. Hematology 10: 225-235, 2005.
37. Huang S and Ingber DE: Shape-dependent control of cell growth, differentiation, and apoptosis: switching between attractors in cell regulatory networks. Exp Cell Res 261: 91-103, 2000.
38. Itoh H, Komatsuda A, Wakui H, Miura AB and Tashima. Y: Mammalian HSP60 is a major target for an immunosuppressant mizoribine. J Biol Chem 274: 35147-35151, 1999.
39. Nadler SG, Tepper MA, Schacter B and Mazzucco CE: Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 258: 484-486, 1992.
40. Wadhwa R, Sugihara T, Yoshida A, Nomura H, Reddel RR, Simpson R, Maruta H and Kaul SC: Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res 60: 6818-6821, 2000.
41. Xiao L, Lu X and Ruden DM: Effectiveness of hsp90 inhibitors as anti-cancer drugs. Mini Rev Med Chem 6: 1137-1143, 2006.
42. Sreedhar AS, Nardai G and Csermely P: Enhancement of complement-induced cell lysis: a novel mechanism for the anticancer effects of Hsp90 inhibitors. Immunol Lett 92: 157-161, 2004.
43. Whitesell L, Minmaugh EG, De CB, Myers CE and Neckers LM: Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91: 8324-8318, 1994.
44. Supko JG, Hickman RL, Grever MR and Malspeis L: Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36: 305-315, 1995.
45. Sausville EA, Tomaszewski JE and Ivy P: Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 3: 377-383, 2003.
46. Schulte TW and Neckers LM: The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42: 273-279, 1998.
47. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC and Burrows FJ: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410, 2003.
48. Munster PN, Marchion DC, Basso AD and Rosen N: Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res 62: 3132-3137, 2002.
49. De Candia P, Solit DB, Giri D, Brogi E, Siegel PM, Olshen AB, Muller WJ, Rosen N and Benezra R: Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/ neu-dependent breast tumors. Proc Nad Acad Sci USA 100: 12337-12342, 2003.
50. Solit DB and Rosen N: Hsp90: a novel target for cancer therapy. Curr Top Med Chem 6: 1205-1214, 2006.
51. Basso AD, Solit DB, Munster PN and Rosen N: Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21: 1159-1166, 2002.
52. Neck-ers L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8: S55-S61, 2002.
53. Soti C, Nagy E, Giricz Z, Vigh L, Csermely P and Ferdinandy P: Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 146: 769-780, 2005.
54. Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y and Neckers LM: The Hsp90 inhibitor geldanamycin selectively sensitizes BcrAbl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 15: 1537-1543, 2001.